{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:53:30Z","timestamp":1782150810865,"version":"3.54.5"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","award":["PR\u00d3-ESTADO - Project 01.02.016301.00649\/2021 - Resolutions 002\/2008, 007\/2018, and 005\/2019"],"award-info":[{"award-number":["PR\u00d3-ESTADO - Project 01.02.016301.00649\/2021 - Resolutions 002\/2008, 007\/2018, and 005\/2019"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"name":"XP Investimentos","award":["57th work plan of the Unidos Contra a COVID-19"],"award-info":[{"award-number":["57th work plan of the Unidos Contra a COVID-19"]}]},{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","award":["EDITAL N\u00ba 038\/2022 - PDPG\/CAPES\/FAPEAM - COORDENADOR\/AUX\u00cdLIO FINANCEIRO"],"award-info":[{"award-number":["EDITAL N\u00ba 038\/2022 - PDPG\/CAPES\/FAPEAM - COORDENADOR\/AUX\u00cdLIO FINANCEIRO"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","award":["National Visiting Research Fellowship II"],"award-info":[{"award-number":["National Visiting Research Fellowship II"]}],"id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    CoronaVac, an inactivated SARS-CoV-2 vaccine, was one of the first deployed during the COVID-19 pandemic. Given the limited vaccine availability and the urgent need to assess effectiveness in target populations, a risk-based allocation clinical trial was designed to generate evidence under the ethical and logistical constraints at the beginning of the COVID-19 vaccination. In Manaus, Brazil, participants working in public service (education and public safety) aged 18\u201349 years were assessed regarding the risk of severe COVID-19 disease. Participants with one or more comorbidities, who were considered at higher risk of severe COVID-19 outcomes if infected, were allocated to early vaccination, while participants without comorbidities were enrolled as an unvaccinated comparison group. Blood samples were collected before each vaccine dose (D0 and D28) and during in-person follow-up visits (D90 and D180). Additional information was obtained through phone calls. Clinical cases of COVID-19, hospitalizations, deaths, and antibody titrations were the evaluated endpoints, considered after the second week following the second dose of the vaccine. A total of 6,226 participants were included: 1,139 in the low-risk group, and 5,087 in the high-risk vaccinated group. COVID-19 incidence was statistically significantly lower (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) in the vaccinated group at D28 (5.2% vs. 40.9%) and D90 (10.3% vs 31.6%). Hospitalization and death rates were low, with no difference observed between the groups. There was a decline in highly reactive titers at D180 in the vaccinated group. This pioneer risk-based allocation clinical trial provided evidence that CoronaVac reduced the risk of severe COVID-19 outcomes among individuals with comorbidities, effectively aligning their risk with that of lower-risk, unvaccinated individuals. Beyond its clinical implications, the study underscores the importance of adaptive, real-world research designs in rapidly generating actionable evidence in response to emerging public health threats.\n                  <\/jats:p>\n                  <jats:p>\n                    ClinicalTrials.gov Registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04789356\" xlink:type=\"simple\">NCT04789356<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0351566","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:40:12Z","timestamp":1782150012000},"page":"e0351566","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of CoronaVac in a pioneer risk-based allocation clinical trial during the COVID-19 pandemic"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-2852","authenticated-orcid":true,"given":"Alex","family":"Martins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Felipe","family":"Bosco Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joabi","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-7227","authenticated-orcid":true,"given":"Fab\u00edola Mendon\u00e7a","family":"da Silva Chui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriela","family":"Almeida Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Honorato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Sim\u00e3o","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika Oliveira","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca Linhares","family":"Abreu-Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salete","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Vilhena","family":"Silva-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Sachett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Maia","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-9491","authenticated-orcid":true,"given":"Gabriel Santos","family":"Mouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jady Shayenne Mota","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djane Clarys","family":"Ba\u00eda-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-3763","authenticated-orcid":true,"given":"Jos\u00e9 Diego","family":"Brito-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1275-5940","authenticated-orcid":true,"given":"Karina Pinheiro","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maur\u00edcio Lacerda","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuelton","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Naveca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7307-8851","authenticated-orcid":true,"given":"Vanderson","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Almeida-Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisely","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio","family":"Ranzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paula","family":"Mour\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-9985","authenticated-orcid":true,"given":"Marcus","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"6","key":"pone.0351566.ref001","article-title":"Factors, enablers and challenges for COVID-19 vaccine development","volume":"8","author":"J-L Excler","year":"2023","journal-title":"BMJ Glob Health"},{"key":"pone.0351566.ref002","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2202669","article-title":"Delivering Pandemic Vaccines in 100 Days \u2014 What Will It Take?","volume":"387","author":"M Saville","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"pone.0351566.ref003","doi-asserted-by":"crossref","first-page":"945930","DOI":"10.3389\/fimmu.2022.945930","article-title":"A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines","volume":"13","author":"X He","year":"2022","journal-title":"Front Immunol"},{"key":"pone.0351566.ref004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.37201\/req\/122.2022","article-title":"Insights for COVID-19 in 2023","volume":"36","author":"FJ Mart\u00edn S\u00e1nchez","year":"2023","journal-title":"Rev Esp Quimioter"},{"issue":"7","key":"pone.0351566.ref005","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S2213-2600(23)00217-5","article-title":"WHO ends the COVID-19 public health emergency","volume":"11","author":"T Burki","year":"2023","journal-title":"Lancet Respir Med"},{"key":"pone.0351566.ref006","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.vacune.2023.05.001","article-title":"The end of COVID-19 public health emergency of international concern (PHEIC): And now what?","volume":"24","author":"N Torner","year":"2023","journal-title":"Vacunas (English Edition)"},{"key":"pone.0351566.ref007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile","volume":"385","author":"A Jara","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"pone.0351566.ref008","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/v14020305","article-title":"CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant","volume":"14","author":"MJ Fumagalli","year":"2022","journal-title":"Viruses"},{"key":"pone.0351566.ref009","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1473-3099(22)00140-2","article-title":"Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study","volume":"22","author":"T Cerqueira-Silva","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0351566.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00327-1","article-title":"Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study","volume":"4","author":"NE Aikawa","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"10229","key":"pone.0351566.ref011","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"F Zhou","year":"2020","journal-title":"Lancet"},{"issue":"7821","key":"pone.0351566.ref012","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"EJ Williamson","year":"2020","journal-title":"Nature"},{"issue":"8","key":"pone.0351566.ref013","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(20)30285-0","article-title":"Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study","volume":"8","author":"P Baqui","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"5","key":"pone.0351566.ref014","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2105\/AJPH.86.5.691","article-title":"Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal","volume":"86","author":"MO Finkelstein","year":"1996","journal-title":"Am J Public Health"},{"key":"pone.0351566.ref015","unstructured":"Minist\u00e9rio da Sa\u00fade. Plano nacional de operacionaliza\u00e7\u00e3o da vacina\u00e7\u00e3o contra Covid-19. 2022. https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/saude-de-a-a-z\/c\/covid-19\/publicacoes-tecnicas\/guias-e-planos\/plano-nacional-de-operacionalizacao-da-vacinacao-contra-covid-19.pdf\/view"},{"key":"pone.0351566.ref016","unstructured":"U.S. FOOD and Drug Administration C for BE and research. Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry. https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-regulatory-information 2025 March 26."},{"key":"pone.0351566.ref017","doi-asserted-by":"crossref","first-page":"1002576","DOI":"10.3389\/fimmu.2022.1002576","article-title":"Design and performance characteristics of the Elecsys anti-SARS-CoV-2 S assay","volume":"13","author":"K Taffertshofer","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"pone.0351566.ref018","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1177\/0962280220930055","article-title":"Robustness of risk-based allocation of resources for disease prevention","volume":"29","author":"MH Gail","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"pone.0351566.ref019","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ejor.2023.04.001","article-title":"Risk-based allocation of COVID-19 personal protective equipment under supply shortages","volume":"310","author":"G Baloch","year":"2023","journal-title":"Eur J Oper Res"},{"issue":"2","key":"pone.0351566.ref020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/03605310701255750","article-title":"Clinical equipoise and the incoherence of research ethics","volume":"32","author":"FG Miller","year":"2007","journal-title":"J Med Philos"},{"issue":"4","key":"pone.0351566.ref021","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-2600(20)30560-9","article-title":"Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data","volume":"9","author":"OT Ranzani","year":"2021","journal-title":"Lancet Respir Med"},{"key":"pone.0351566.ref022","article-title":"Risks of adverse outcomes for hospitalized COVID-19 patients during the four waves in Brazil according to SARS-CoV-2 variants, age group, and vaccine status","volume":"15","author":"NS Hojo-Souza","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"pone.0351566.ref023","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-022-01701-w","article-title":"Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil","volume":"28","author":"T Cerqueira-Silva","year":"2022","journal-title":"Nat Med"},{"key":"pone.0351566.ref024","doi-asserted-by":"crossref","first-page":"112452","DOI":"10.1016\/j.psychres.2019.06.027","article-title":"Experimental and quasi-experimental designs in implementation research","volume":"283","author":"CJ Miller","year":"2020","journal-title":"Psychiatry Res"},{"issue":"10","key":"pone.0351566.ref025","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/cid\/ciy906","article-title":"The Use of Quasi-experimental Designs for Vaccine Evaluation","volume":"68","author":"JA Lopez Bernal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0351566.ref026","first-page":"100025","article-title":"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study","volume":"1","author":"MDT Hitchings","year":"2021","journal-title":"Lancet Reg Health Am"},{"issue":"6","key":"pone.0351566.ref027","doi-asserted-by":"crossref","first-page":"2096970","DOI":"10.1080\/21645515.2022.2096970","article-title":"CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2","volume":"18","author":"L Jin","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"10273","key":"pone.0351566.ref028","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence","volume":"397","author":"EC Sabino","year":"2021","journal-title":"Lancet"},{"issue":"6526","key":"pone.0351566.ref029","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.abe9728","article-title":"Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic","volume":"371","author":"LF Buss","year":"2021","journal-title":"Science"},{"issue":"9","key":"pone.0351566.ref030","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"J Wei","year":"2021","journal-title":"Nat Microbiol"},{"issue":"11","key":"pone.0351566.ref031","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/CM9.0000000000001573","article-title":"Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials","volume":"134","author":"H-X Pan","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"pone.0351566.ref032","doi-asserted-by":"crossref","first-page":"126516","DOI":"10.1016\/j.vaccine.2024.126516","article-title":"Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease","volume":"43","author":"NE Dean","year":"2025","journal-title":"Vaccine"},{"key":"pone.0351566.ref033","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13259","article-title":"Reply to the John Speakman critique of \u201cImpact of obesity on COVID-19 related mortality: A comment on estimates in Popkin et al (2020)\u201d published in Obesity Reviews","volume":"22","author":"BM Popkin","year":"2021","journal-title":"Obesity Reviews"},{"issue":"1","key":"pone.0351566.ref034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.120.047659","article-title":"Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms","volume":"142","author":"N Sattar","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"pone.0351566.ref035","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2105\/AJPH.86.5.696","article-title":"Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples","volume":"86","author":"MO Finkelstein","year":"1996","journal-title":"Am J Public Health"},{"issue":"6544","key":"pone.0351566.ref036","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil","volume":"372","author":"NR Faria","year":"2021","journal-title":"Science"},{"issue":"1","key":"pone.0351566.ref037","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02366-21","article-title":"Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil","volume":"10","author":"FG Naveca","year":"2022","journal-title":"Microbiol Spectr"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:40:25Z","timestamp":1782150025000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351566"}},"subtitle":[],"editor":[{"given":"Dipendra","family":"Khatiwada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351566","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}